Tumour-associated macrophages (TAMs) are now recognized as key conductors of the tumour immune microenvironment. Rather than behaving as a fixed cell type, TAMs display striking phenotypic and functional plasticity, allowing them to reshape immune activity as tumours evolve. A growing body of research suggests that RNA editing—chemical modification of RNA transcripts—can help drive this rapid behavioural switching. However, which molecular pathways tune RNA editing to macrophage fate has remained unclear.
In a new study published 24 July 2026, Yang, Li, Lei and colleagues investigated the role of APOBEC3, a family of RNA/DNA base-editing enzymes, in controlling macrophage function during anti-tumour responses. APOBEC3 proteins are well known for their capacity to introduce cytidine-to-uracil changes in nucleic acids, generating edited transcripts with altered coding potential and regulatory outputs. The authors asked whether host APOBEC3 deficiency would redirect macrophage behaviour in ways that favour immune control of cancer.
Their work links APOBEC3 loss to a form of metabolic rewiring in macrophages. Specifically, the researchers report lipid metabolic reprogramming that changes how macrophages process and store fats, which can influence membrane composition, signalling pathways, and ultimately immune effector programs. In the tumour context, this metabolic shift appears to move macrophages toward a more immune-supportive state.
Mechanistically, the paper connects the editing landscape to macrophage function. Because RNA editing can affect transcript stability and protein expression, altered editing patterns in APOBEC3-deficient hosts are proposed to reshape gene expression networks governing lipid handling. While the exact edited targets are still a moving frontier, the study provides a functional bridge between base-editing capacity and macrophage metabolic phenotype.
Functionally, the authors observe enhanced anti-tumour immunity associated with host APOBEC3 deficiency. By promoting macrophage metabolic states that better support immune attack, the study suggests that TAMs can be re-educated through changes in host editing machinery rather than direct reprogramming of immune cells alone.
This is more than a metabolic story: it also reframes APOBEC3 as a host regulator of tumour immunology, not just a molecular editor. The findings imply that RNA editing enzymes can influence immune outcomes by steering cellular energetics and lipid pathways—processes that are often exploited by tumours to suppress immunity.
Finally, the work adds to a broader trend in viral and immune science: editing-related enzymes are emerging as gatekeepers of immune cell function. Although APOBEC3 is frequently discussed in antiviral contexts, these results extend its relevance to cancer, highlighting the possibility that manipulating host editing capacity could become a strategy for boosting anti-tumour immunity.
Subject of Research: Tumour-associated macrophages, RNA base editing, anti-tumour immunity
Article Title: Lipid metabolic reprogramming of macrophage by host APOBEC3 deficiency enhances anti-tumor immunity.
Article References: Yang, Y., Li, F., Lei, M. et al. (2026) Br J Cancer. https://doi.org/10.1038/s41416-026-03550-7
Image Credits: AI Generated
DOI: https://doi.org/10.1038/s41416-026-03550-7
Keywords:
